AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deNOV 32 min read$EVAX

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

Original reporting
finanznachrichten.de
Published Nov 3, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The disclosed 75% ORR and systemic immune modulation suggest a potentially differentiated product, which could accelerate partnership talks or funding.

02

Market read

First‑time disclosure of robust phase‑2 data for a personalized cancer vaccine, likely to move EVAX and influence peer biotech valuations.

03

What to watch

Regulatory timelines and manufacturing scalability for personalized vaccines remain uncertain.

Relevance 8/10Novelty 8/10Timing: presentation at SITC conference Nov 6‑7, 2026

Background

Evaxion is a Copenhagen‑based clinical‑stage TechBio firm using AI‑Immunology to design personalized peptide vaccines. EVX‑01 is being tested in advanced melanoma in combination with pembrolizumab.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion (NASDAQ:EVAX) will present new phase‑2 biomarker data showing a 75% objective response rate for its personalized cancer vaccine EVX‑01 at the SITC 2026 Annual Meeting.

Expected impact

likely upward pressure as market prices in the strong ORR and systemic immune response data.

Evidence & confidence

Phase‑2 results with high response rates are material for a clinical‑stage biotech and often trigger price appreciation.

Market effects

Sector

strengthens outlook for AI‑driven personalized cancer vaccine platforms and may boost peer biotech valuations.

Regional

European and US biotech markets could see modest gains on the back of the data.

Global

Adds positive momentum to the global oncology immunotherapy sector.

Counterpoint

What could challenge this read

If the data cannot be replicated in larger trials, the initial hype may reverse quickly.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing AI‑driven immunotherapies.

  • company
    Merck & Co.

    Provider of pembrolizumab (Keytruda) used in the trial.

Read at source← All news

StoryEvaxion to present phase‑2 biomarker data for personalized cancer vaccine EVX‑01 at SITC 2026

Related articles

NOV 4
$EVAXMed

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

finanznachrichten.de2 min
OCT 23
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de3 min
OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min